PHS
STLN

Pekin Hardy Strauss’s Starling Oncology STLN Stock Holding History

Pekin Hardy Strauss’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$174K Hold
32,000
– – 0.02% 481
2026
Q1 		$98.2K Buy
32,000
+22,000
+220% +$67.5K 0.01% 459
2025
Q4 		$35.6K Buy
+10,000
New +$37.1K ﹤0.01% 450

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Pekin Hardy Strauss's STLN Position: Q2 2026 in Review

Pekin Hardy Strauss held its Starling Oncology (STLN) position steady in Q2 2026 at 32,000 shares worth $174K. The position accounts for 0.02% of the portfolio, ranked #481.

Pekin Hardy Strauss first reported a position in STLN in Q4 2025 and has held it in 3 quarters since. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Pekin Hardy Strauss held 32,000 shares of Starling Oncology worth $174K as of Q2 2026.
  • Pekin Hardy Strauss left its Starling Oncology share count unchanged in Q2 2026.
  • Starling Oncology made up 0.02% of Pekin Hardy Strauss's portfolio in Q2 2026, its #481 holding.
  • Pekin Hardy Strauss first reported a position in Starling Oncology in Q4 2025 and has held it in 3 quarters since.
  • 119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Pekin Hardy Strauss's 13F filing for Q2 2026, filed 30 Jul 2026.